On November 10, 2021 Vyant Bio, Inc. ("Vyant Bio", "Company") (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases (Press release, Vyant Bio, NOV 10, 2021, View Source [SID1234595280]). Today, Vyant Bio reported that it will be presenting at the Q4 Investor Summit Micro & Small Cap Conference ("Q4 Investor Summit"). The event is being held virtually from November 16-17, 2021.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Conference Date: November 16-17, 2021 (Tuesday-Wednesday)
Presentation Time: 11:45am – 12:15pm ET – Wednesday, November 17, 2021
Presentation Link: View Source
1:1 Availability: 8am – 4:45pm ET daily
Event Registration: View Source
During the presentation, Vyant Bio’s Chief Executive Officer, Jay Roberts, will highlight the Company’s addition of its Chief Scientific Officer, progress being made with its drug discovery programs, noteworthy collaborations and partnerships, and the broader going-forward corporate strategy.
The presentation will be webcast and an archived recording will be made available in the Investors’ section of the Vyant Bio website and also on the Q4 Investor Summit website for 90 days following the event.
If you are an investor and would like to attend the Q4 Investor Summit, please click on the following link (View Source) to register. Once your registration is confirmed, you will be prompted to log into the conference website and will be able to request a one-on-one meeting with the Company.
Vyant Bio will also be available for virtual outside 1:1 meetings both during and after the Q4 Investor Summit Micro & Small Cap Conference. Please contact Jennifer K. Zimmons, PhD at [email protected] or +1 917.214.3514 for scheduling.